Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome

Bayer’s Vitrakvi (larotrectinib) Receives EMA’s Approval as the First Tumor Agonist in Europe


  • Bayer to take care of subsequent clinical development and commercialization. Evotec to receive €6.5M up front, €10M research payments over five years, up to €330M milestones pre-clinical and sales milestones, royalties on sales
  • The companies will supply the drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options. Additionally, the deal will have access to targets partnership between Celmatix and Evotec in Oct 2019  
  • In 2012, Bayer and Evotec signs a five-year multi-target agreement for three clinical and one pre-clinical drug candidates currently involved to treat endometriosis. Additionally, in 2016, the companies collaborated to develop therapies for kidney disease

Click here to read full press release/ article | Ref: Bayer | Image: Twitter